Yahoo Finance has some. No chart, though.
No matter if you are a bull or bear, credit is due to Northwest Biotherapeutics. This tiny company, which began the week with a $29 million market cap, is more than a blip on the radar now.
With limited approval in Switzerland to make its immunotherapy vaccine available to brain cancer patients, NWBO.OB is on the map. After taking a major bump down after running up 294% to $7.33, NWBO now sits at $4.20 with a pullback of 42% from the high.
Monday's humongous run was tempered by selloffs on Tuesday and today. Mind you, volume went from 3.9 million shares on Monday to 2.9 mil on Tuesday. Today? A mere 1.2 million shares traded — still a significant number considering the float is a measly 4.17 million. The current PPS is more than double what it was after Friday's close ($2.10).
The decrease in volume may indicate that the selloff is nearly done, and perhaps NWBO has reached a nice, new bottom. The question now that the daytraders are filtering out, is how much is the Swiss deal going to be worth? There no numbers to work with, but Wolfeman at Investor Village has put together a reasonable list of facts that breaks down the information as well as any.
Still, all the investing and trading are based on the news and speculation. Of course, there's no other headline that grabs attention like "First Cancer Vaccine available."
For biotech investors with an eye on the future — and Northwest Bio's vaccine will be marketed in this quarter — this is definitely a situation worth monitoring. Enter at your own risk.
Disclaimer: Pupule Paul has no position in NWBO.OB.
No comments:
Post a Comment